Michael W Hulse

机构：Prelude Therapeutics Incorporated (United States) · ORCID：0009-0000-7928-1842

发表论文 77 篇 · 总被引 272 次 · h-index 6

代表论文

• Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer (2023 · Nature Cancer · 被引 126)
• PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies (2023 · Cancer Research Communications · 被引 38)
• PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers (2025 · Cancer Research · 被引 20)
• Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers (2023 · Molecular Cancer Therapeutics · 被引 4)
• Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2 (2024 · Cancer Research · 被引 3)
• Abstract 1646: Elucidating the molecular mechanism of action of the first in human SMARCA2 selective degrader PRT3789 (2025 · Cancer Research · 被引 2)